Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program – BioSpace
Eterna Therapeutics, Inc. (Nasdaq: ERNA), based in Cambridge, Massachusetts, is a cutting-edge leader in cell therapies. With a strong focus on developing effective and safe off-the-shelf cell therapies for advanced solid tumors, Eterna Therapeutics has recently announced an exciting new initiative. The company’s Board of Directors has approved a stock repurchase program of up to $1 million of the company’s outstanding common stock.
This strategic move highlights the board’s confidence in Eterna Therapeutics’ long-term vision and dedication to maximizing shareholder value. The stock repurchase program allows the company to buy back shares through various methods, such as open market transactions or private negotiations, in accordance with securities laws. The timing and quantity of the repurchases will be determined by the company’s management, considering market conditions and stock prices, among other factors.
It’s important to note that this stock repurchase program does not have a fixed end date and may be adjusted or terminated at any time without prior notice. Sanjeev Luther, President and CEO of Eterna Therapeutics, expressed confidence in the company’s direction with this buyback program.
Eterna Therapeutics is known for its innovative approach in using induced allogenic mesenchymal stem cell technology to deliver pro-inflammatory cytokines to tumor microenvironments for anti-tumor immunity. The company’s key product, ERNA-101, focuses on advanced solid tumors like triple-negative breast cancer and platinum-resistant, TP53-mutant ovarian cancer.
With a commitment to groundbreaking research and a deep focus on patient outcomes, Eterna Therapeutics continues to make a positive impact on the field of cell therapies. For more information on their work and initiatives, visit their website at https://www.eternatx.com/.
Please note that this press release contains forward-looking statements within the meaning of securities regulations. These statements are subject to various risks and uncertainties that could impact the company’s actual results.
